KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) EPS (Weighted Average and Diluted) (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 147.17%
Dec 31, 2025 -50.93%
Sep 30, 2025 68.75%
Jun 30, 2025 -46.67%
Mar 31, 2025 2,900.00%
Dec 31, 2024 -93.33%
Sep 30, 2024 -27.71%
Jun 30, 2024 114.09%
Mar 31, 2024 -777.01%
Dec 31, 2023 -6.45%
Sep 30, 2023 -6.06%
Jun 30, 2023 -7.48%
Mar 31, 2023 12.63%
Dec 31, 2022 26.67%
Sep 30, 2022 13.64%
Jun 30, 2022 11.86%
Mar 31, 2022 -44.86%
Dec 31, 2021 55.07%
Sep 30, 2021 46.81%
Jun 30, 2021 -47.19%
Mar 31, 2021 120.00%
Dec 31, 2020 -642.68%
Sep 30, 2020 2,150.00%
Jun 30, 2020 88.24%
Mar 31, 2020 38.18%
Dec 31, 2019 -166.27%
Sep 30, 2019 -4.60%
Jun 30, 2019 -16.35%
Mar 31, 2019 46.48%
Dec 31, 2018 -38.79%
Sep 30, 2018 404.35%
Jun 30, 2018 -74.73%
Mar 31, 2018 164.08%
Dec 31, 2017 -378.43%
Sep 30, 2017 -8.93%
Jun 30, 2017 -40.43%
Mar 31, 2017 77.36%
Dec 31, 2016 -26.39%
Sep 30, 2016 4.35%
Jun 30, 2016 -2.82%
Mar 31, 2016 691.67%
Dec 31, 2015 -128.57%
Sep 30, 2015 625.00%
Jun 30, 2015 -111.27%
Mar 31, 2015 7,000.00%
Dec 31, 2014 -97.67%
Sep 30, 2014 115.00%
Jun 30, 2014 -64.29%
Mar 31, 2014 27.27%
Dec 31, 2013 4.76%
Sep 30, 2013 31.25%
Jun 30, 2013 -13.51%
Mar 31, 2013 -33.93%
Dec 31, 2012 230.23%
Sep 30, 2012 -213.16%
Jun 30, 2012 -40.63%
Mar 31, 2012 28.00%
Dec 31, 2011 -10.71%
Sep 30, 2011 7.69%
Jun 30, 2011 -8.77%
Mar 31, 2011 103.57%
Dec 31, 2010 -49.09%
Sep 30, 2010 3.77%
Jun 30, 2010 23.26%
Mar 31, 2010 30.30%
Dec 31, 2009 -31.25%
Sep 30, 2009 9.09%
Jun 30, 2009 37.50%